Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Rotella

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
Novel compounds for the treatment of neurodegenerative diseases: patent highlightDavid P Rotella
Bioorganic & Medicinal Chemistry Letters|October 16, 2012
Recent results in protein kinase inhibition for tropical diseasesDavid P Rotella
ACS Medicinal Chemistry Letters|October 18, 2023
Patrick M. Woster Memorial CommentaryDavid P Rotella, Gunda Georg
Journal of Medicinal Chemistry|September 8, 2023
Patrick M. Woster Memorial CommentaryDavid P Rotella, Gunda Georg
Pharmaceutical Patent Analyst|November 19, 2013
Welcome to Pharmaceutical Patent Analyst. ForewordLyn H Jones, David P Rotella, Gino D'Oca
Journal of Medicinal Chemistry|August 21, 2014
Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitorsRohit Bhat, Sreedhar R Tummalapalli, David P Rotella
Plos One|November 27, 2013
The spectral properties of (-)-epigallocatechin 3-O-gallate (EGCG) fluorescence in different solvents: dependence on solvent polarityVladislav Snitsarev, Michael N Young, Ross M S Miller, et al.
Archives of Biochemistry and Biophysics|February 1, 2017
Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compoundsYacoba V T Minnow, Ronald Goldberg, Sreedhar R Tummalapalli, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2014
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitorsRohit Bhat, Amna T Adam, Jungeun Jasmine Lee, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2014
Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitorsRohit Bhat, Amna T Adam, Jungeun Jasmine Lee, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
ACS Medicinal Chemistry Letters|June 6, 2014
Novel compounds for the treatment of neurodegenerative diseases: patent highlightDavid P Rotella
Bioorganic & Medicinal Chemistry Letters|October 16, 2012
Recent results in protein kinase inhibition for tropical diseasesDavid P Rotella
ACS Medicinal Chemistry Letters|October 18, 2023
Patrick M. Woster Memorial CommentaryDavid P Rotella, Gunda Georg
Journal of Medicinal Chemistry|September 8, 2023
Patrick M. Woster Memorial CommentaryDavid P Rotella, Gunda Georg
Pharmaceutical Patent Analyst|November 19, 2013
Welcome to Pharmaceutical Patent Analyst. ForewordLyn H Jones, David P Rotella, Gino D'Oca
Journal of Medicinal Chemistry|August 21, 2014
Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitorsRohit Bhat, Sreedhar R Tummalapalli, David P Rotella
Plos One|November 27, 2013
The spectral properties of (-)-epigallocatechin 3-O-gallate (EGCG) fluorescence in different solvents: dependence on solvent polarityVladislav Snitsarev, Michael N Young, Ross M S Miller, et al.
Archives of Biochemistry and Biophysics|February 1, 2017
Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compoundsYacoba V T Minnow, Ronald Goldberg, Sreedhar R Tummalapalli, et al.
Bioorganic & Medicinal Chemistry Letters|August 9, 2014
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitorsRohit Bhat, Amna T Adam, Jungeun Jasmine Lee, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2014
Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitorsRohit Bhat, Amna T Adam, Jungeun Jasmine Lee, et al.
Pageof 6